Nu-Med Plus (NUMD) Liabilities and Shareholders Equity (2011 - 2026)
Nu-Med Plus' (NUMD) quarterly Liabilities and Shareholders Equity came in at $12909.0 in Q2 2026, up 58.14% year-over-year from $8163.0 in Q2 2025, and up 63.18% quarter-over-quarter from $7911.0 in Q4 2025.
Powered by 
Analysis
Nu-Med Plus (NUMD) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Nu-Med Plus has disclosed Liabilities and Shareholders Equity across 16 years of filings, most recently posting $12909.0 for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity rose 58.14% year-over-year to $12909.0; the TTM figure through Jun 2026 stood at $34031.0 (up 15.16% YoY), while the FY2025 annual figure was $7911.0, down 15.6% from the prior year.
- Liabilities and Shareholders Equity came in at $12909.0 for Q2 2026 at Nu-Med Plus, up from $7911.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $79545.0 in Q4 2022 to a low of $3168.0 in Q3 2022.
- Average Liabilities and Shareholders Equity over 5 years is $17492.6, with a median of $9016.0 recorded in 2024.
- Year-over-year, Liabilities and Shareholders Equity plunged 97.22% in 2022 and soared 645.26% in 2023.
- Over 5 years, Liabilities and Shareholders Equity stood at $79545.0 in 2022, then sank by 83.08% to $13456.0 in 2023, then sank by 30.34% to $9373.0 in 2024, then decreased by 15.6% to $7911.0 in 2025, then surged by 63.18% to $12909.0 in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $12909.0 in Q2 2026, $7911.0 in Q4 2025, and $5048.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 20.88 Bn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 93.31 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 47.93 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 45.22 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 13.87 Bn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 31.10 Bn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 6.46 Bn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | 12,909.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12,909.00 |
| Dec 31, 2025 | 7,911.00 |
| Sep 30, 2025 | 5,048.00 |
| Jun 30, 2025 | 8,163.00 |
| Mar 31, 2025 | 5,173.00 |
| Dec 31, 2024 | 9,373.00 |
| Sep 30, 2024 | 6,841.00 |
| Jun 30, 2024 | 11,041.00 |
| Mar 31, 2024 | 9,016.00 |
| Dec 31, 2023 | 13,456.00 |
| Sep 30, 2023 | 13,748.00 |
| Jun 30, 2023 | 36,547.00 |
| Mar 31, 2023 | 59,069.00 |
| Dec 31, 2022 | 79,545.00 |
| Sep 30, 2022 | 3,168.00 |
| Jun 30, 2022 | 8,440.00 |
| Mar 31, 2022 | 7,926.00 |
| Dec 31, 2021 | 22,163.00 |
| Sep 30, 2021 | 51,236.00 |
| Jun 30, 2021 | 89,130.00 |